Navigation Links
Palatin Technologies To Participate In The 25th Annual Piper Jaffray Healthcare Conference
Date:12/2/2013

CRANBURY, N.J., Dec. 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that Dr. Carl Spana, the Company's chief executive officer, will participate in a "Fireside Chat" at the 25th Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ET on December 4, 2013. The conference will be held at the New York Palace hotel in New York City.  A live audio broadcast will be available on the "Investors" section of Palatin's website at www.palatin.com. The live audio broadcast will be available through December 10, 2013.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
2. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
3. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
4. Palatin Technologies To Present At The 25th Annual ROTH Conference
5. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
6. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
8. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
9. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
11. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... The American Journal of ... research, reviews and editorials addressing developments and pathways ... published a provocative article exploring the role of ... potential treatment of prostate cancer. , The ... the possibility that there could be a connection ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... ROCKVILLE, Md., May 5 Sequella, Inc., a clinical-stage ... today the start of its Phase 1B trial for ... volunteers. SQ109, a new diamine antibiotic intended to replace ... and simplify patient therapy, was granted U.S. FDA Fast ...
... Mass., May 5 Syrinx Consulting Corporation ... that delivers easy-to-use .Net and SharePoint applications ... contract for approximately $100,000 with a leading biopharmaceutical company ... migrating thousands of users and gigabytes of data from ...
... Breakthrough biotechnology research is providing new applications ... and diabetes, two leading health concerns among consumers. ... Advana Science, www.advanascience.com , will ... this dynamic consumer healthy category at VitaFoods International ...
Cached Biology Technology:Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109 2Syrinx Wins Contract with Leading Pharmaceutical Company for SharePoint 2007 Services 2Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications 2
(Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
(Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... fund structured by JPMorgan Chase & Co. (NYSE: JPM) ... the first time, allow individual and institutional investors the ... the potential to save millions of lives in low-income ... pioneering group of investors including anchor support from ...
... imply that it is hard to fool the brain by ... sweet solutions is driven to a great extent by the ... is attributed to sugars compared to artificial sweeteners. Professor ... School of Medicine USA, says:,"The consumption of high-calorie beverages is ...
... vaccine after using the 2009 pandemic as a natural experiment ... Researchers at Imperial College London asked volunteers to donate ... underway and report any symptoms they experienced over the next ... severe illness had more CD8 T cells, a type of ...
Cached Biology News:New investment fund will advance late-stage vaccines, other global health technologies 2New investment fund will advance late-stage vaccines, other global health technologies 3New investment fund will advance late-stage vaccines, other global health technologies 4The brain cannot be fooled by artificial sweeteners 2Scientists closer to universal flu vaccine after pandemic 'natural experiment' 2